Abstract
To investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in patients with unresectable hepatocellular carcinoma (HCC) compared with conventional transarterial chemoembolization (cTACE) and prognostic factors for efficacy. 64 HCC patients were analyzed in this retrospective cohort study, among which 36 patients received DEB-TACE and 28 received cTACE. Treatment response was assessed by CT/MRI according to mRECIST criteria, and PFS was evaluated. No difference was observed regarding CR, PR, SD, PD, ORR and DCR at 3 months post treatment (all P>0.05) between DEB-TACE and cTACE groups. Although the ORR (P = 0.020) and DCR (P = 0.047) were notably increased in DEB-TACE group compared with cTACE group. And univariate and multivariate logistic regressions revealed that DEB-TACE treatment independently associated with better ORR at 6 months (P = 0.008). Moreover, the PFS in DEB-TACE group was prolonged compared with cTACE group (P = 0.028), and multivariate Cox’s regression revealed that DEB-TACE treatment was independently correlated with better PFS. In addition, despite that the levels of all laboratory indexes related to liver function worsened at 3 days post operation in two groups, the levels of AST (P = 0.021) and ALT (P = 0.028) at 3 days were notably lower in the DEB-TACE group when compared with cTACE group. DEB-TACE was superior to cTACE in unresectable HCC patients in terms of increased treatment responses, prolonged PFS and less liver dysfunction.Table 1Treatment Response in DEB-TACE and cTACE GroupDEB-TACE GroupcTACE GroupP Value3 months after operationCR5(13.9)1(3.6)0.219ORR29(80.6)18(64.3)0.144DCR34(94.5)24(85.7)0.6466 months after operationCR3(8.3)0(0.0)0.250ORR28(77.8)14(50.0)0.020DCR33(91.7)19(67.9)0.047 Open table in a new tab
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
